e-learning
resources
Munich 2006
Tuesday 05.09.2006
Quality of life in various respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study
G. Raghu, K. K. Brown, J. Behr, R. M. du Bois, T. E. King (Seattle, Denver, San Francisco, United States Of America; Munich, Germany; London, United Kingdom)
Source:
Annual Congress 2006 - Quality of life in various respiratory diseases
Session:
Quality of life in various respiratory diseases
Session type:
Oral Presentation
Number:
3359
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Raghu, K. K. Brown, J. Behr, R. M. du Bois, T. E. King (Seattle, Denver, San Francisco, United States Of America; Munich, Germany; London, United Kingdom). Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study. Eur Respir J 2006; 28: Suppl. 50, 3359
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018
Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005
COVID-19: Current Challenges in ILD
Source: ERS webinar 2020: COVID-19: Current Challenges in ILD
Year: 2020
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF clinical
Year: 2016
Contemporary surgical issues in NSCLC treatment
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007
Interstitial fibrosis with a nodule
Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session
Year: 2007
Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD)
Source: Eur Respir J 2004; 24: Suppl. 48, 533s
Year: 2004
Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment I
Year: 2016
Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Histopathological assessment and classification
Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias
Year: 2006
Interstitial lung disease
Source: Eur Respir Rev 2013; 22: 26-32
Year: 2013
The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2003 Dec 01;22(6):906-911
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept